Tamnorzatinib
As of the edition of 20 October 2026, Tamnorzatinib is a small molecule: in active development; acts on AXL and MERTK.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Small molecule
- Registered trials
- 4, 1 stopped early
- Disease areas
- Cancer; Blood and lymph; Digestive system; Hormones; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 2 | 1 | 0 |
| Phase 2 | 1 | 0 | 0 | 1 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Ono Pharmaceutical | Lead sponsor of trials | 2017 to now |